Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor conferences.
B. Riley Securities’ 3rd Annual Oncology Conference
5th Annual Guggenheim Oncology Days
Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Cautionary Note on Forward-Looking Statements for Allogene
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Game Changer - Helium
IoT Evolution Expo, The Smart City Event, Industrial IoT, 5G Expo, 6G Expo Conference Sessions
Building a Scalable MSP Model